Top

Cancer Cell International

Published in:

Open Access 01-12-2021 | Primary research

CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway

Authors: Wanqiong Yuan, Feng Wei, Hanqiang Ouyang, Xiaoqing Ren, Jing Hang, Xiaoning Mo, Zhongjun Liu

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Chordomas are rare, slow-growing and locally aggressive bone sarcomas. At present, chordomas are difficult to manage due to their high recurrence rate, metastasis tendency and poor prognosis. The underlying mechanisms of chordoma tumorigenesis and progression urgently need to be explored to find the effective therapeutic targets. Our previous data demonstrates that EGFR plays important roles in chordoma development and CKLF-like MARVEL transmembrane domain containing (CMTM)3 suppresses gastric cancer metastasis by inhibiting the EGFR/STAT3/EMT signaling pathway. However, the roles and mechanism of CMTM3 in chordomas remain unknown.

Methods

Primary chordoma tissues and the paired adjacent non-tumor tissues were collected to examine the expression of CMTM3 by western blot. The expression of CMTM3 in chordoma cell lines was tested by Real-time PCR and western blot. CCK-8 and colony forming unit assay were performed to delineate the roles of CMTM3 in cell proliferation. Wound healing and Transwell assays were performed to assess cell migration and invasion abilities. A xenograft model in NSG mice was used to elucidate the function of CMTM3 in vivo. Signaling pathways were analyzed by western blot and IHC. RNA-seq was performed to further explore the mechanism regulated by CMTM3 in chordoma cells.

Results

CMTM3 expression was downregulated in chordoma tissues compared with paired normal tissues. CMTM3 suppressed proliferation, migration and invasion of chordoma cells in vitro and inhibited tumor growth in vivo. CMTM3 accelerated EGFR degradation, suppressed EGFR/STAT3/EMT signaling pathway, upregulated TP53 expression and enriched the TP53 signaling pathway in chordoma cells.

Conclusions

CMTM3 inhibited tumorigenesis and development of chordomas through activating the TP53 signaling pathway and suppressing the EGFR/STAT3 signaling pathway, which suppressed EMT progression. CMTM3 might be a potential therapeutic target for chordomas.

Available only for authorised users

Salisbury JR. The pathology of the human notochord. J Pathol. 1993;171(4):253–5. https://doi.org/10.1002/path.1711710404.CrossRefPubMed

Williams BJ, Raper DM, Godbout E, Bourne TD, Prevedello DM, Kassam AB, Park DM. Diagnosis and treatment of chordoma. J Natl Compr Canc Netw. 2013;11(6):726–31. https://doi.org/10.6004/jnccn.2013.0089.CrossRefPubMed

Ailon T, Torabi R, Fisher CG, Rhines LD, Clarke MJ, Bettegowda C, Boriani S, Yamada YJ, Kawahara N, et al. Management of locally recurrent chordoma of the mobile spine and sacrum: a systematic review. Spine (Phila Pa 1976). 2016;41:S193–8. https://doi.org/10.1097/BRS.0000000000001812.CrossRef

Hai B, Ma Y, Liu X. A brief review of chordomas: pathogenesis, prognostic factors and therapeutic targets. Histol Histopathol. 2019;34(5):445–56. https://doi.org/10.14670/HH-18-080.CrossRefPubMed

Yamada Y, Gounder M, Laufer I. Multidisciplinary management of recurrent chordomas. Curr Treat Options Oncol. 2013;14(3):442–53. https://doi.org/10.1007/s11864-013-0247-3.CrossRefPubMed

Fatehi HM, Mansouri A, Alotaibi NM, Hazrati LN, Bernstein M. Metastatic saccrococcygeal chordoma. J Clin Neurosci. 2016;23:149–52. https://doi.org/10.1016/j.jocn.2015.05.036.CrossRef

Stacchiotti S, Casali PG. Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep. 2011;13(4):323–30. https://doi.org/10.1007/s11912-011-0176-x.CrossRefPubMed

Linder M, Glitzner E, Srivatsa S, Bakiri L, Matsuoka K, Shahrouzi P, Dumanic M, Novoszel P, Mohr T, et al. EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO Mol Med. 2018;10(11):e9408. https://doi.org/10.15252/emmm.201809408.CrossRefPubMedPubMedCentral

Huang F, Shi Q, Li Y, Xu L, Xu C, Chen F, Wang H, Liao H, Chang Z, et al. HER2/EGFR-AKT signaling switches TGFbeta from inhibiting cell proliferation to promoting cell migration in breast cancer. Cancer Res. 2018;78(21):6073–85. https://doi.org/10.1158/0008-5472.CAN-18-0136.CrossRefPubMed

10.

Liang C, Ma Y, Yong L, Yang C, Wang P, Liu X, Zhu B, Zhou H, Liu X, et al. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma. Cancer Sci. 2019;110(1):166–79. https://doi.org/10.1111/cas.13875.CrossRefPubMed

11.

Lv D, Li Y, Zhang W, Alvarez AA, Song L, Tang J, Gao WQ, Hu B, Cheng SY, et al. TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma. Nat Commun. 2017;8(1):1454. https://doi.org/10.1038/s41467-017-01731-w.CrossRefPubMedPubMedCentral

12.

He L, Liu X, Yang J, Li W, Liu S, Liu X, Yang Z, Ren J, Wang Y, et al. Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis. Cell Res. 2018;28(9):934–51. https://doi.org/10.1038/s41422-018-0079-6.CrossRefPubMedPubMedCentral

13.

Zhou Q, Huang T, Jiang Z, Ge C, Chen X, Zhang L, Zhao F, Zhu M, Chen T, et al. Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway. Oncogene. 2020;39(10):2140–55. https://doi.org/10.1038/s41388-019-1131-9.CrossRefPubMed

14.

Jiang S, Wang X, Song D, Liu X, Gu Y, Xu Z, Wang X, Zhang X, Ye Q, et al. Cholesterol induces epithelial-to-mesenchymal transition of prostate cancer cells by suppressing degradation of EGFR through APMAP. Cancer Res. 2019;79(12):3063–75. https://doi.org/10.1158/0008-5472.CAN-18-3295.CrossRefPubMed

15.

Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26. https://doi.org/10.1016/j.tcb.2018.12.001.CrossRefPubMed

16.

Caramel J, Ligier M, Puisieux A. Pleiotropic roles for ZEB1 in cancer. Cancer Res. 2018;78(1):30–5. https://doi.org/10.1158/0008-5472.CAN-17-2476.CrossRefPubMed

17.

Gulluoglu S, Tuysuz EC, Sahin M, et al. The role of TNF-alpha in chordoma progression and inflammatory pathways. Cell Oncol (Dordr). 2019;42:663–77. https://doi.org/10.1007/s13402-019-00454-y.CrossRef

18.

Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005;25(17):7432–40. https://doi.org/10.1128/MCB.25.17.7432-7440.2005.CrossRefPubMedPubMedCentral

19.

Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6(3):a26104. https://doi.org/10.1101/cshperspect.a026104.CrossRef

20.

Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, Liu Z, Lin K, Xu-Monette ZY, et al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun. 2014;5:5218. https://doi.org/10.1038/ncomms6218.CrossRefPubMed

21.

Ma J, Chen W, Wang K, Tian K, Li Q, Zhao, et al. Identification of the different roles and potential mechanisms of T isoforms in the tumor recurrence and cell cycle of chordomas. Onco Targets Ther. 2019;12:11777–91. https://doi.org/10.2147/OTT.S232526.CrossRefPubMedPubMedCentral

22.

Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y, Gu W, Huang J, Gui L, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 2001;357(Pt 1):127–35. https://doi.org/10.1042/0264-6021:3570127.CrossRefPubMedPubMedCentral

23.

Han W, Ding P, Xu M, Wang L, Rui M, Shi S, Liu Y, Zheng Y, Chen Y, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics. 2003;81(6):609–17. https://doi.org/10.1016/s0888-7543(03)00095-8.CrossRefPubMed

24.

Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, Li H, Shu XS, Li H, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009;69(12):5194–201. https://doi.org/10.1158/0008-5472.CAN-08-3694.CrossRefPubMed

25.

Di Meo S, Airoldi I, Sorrentino C, Zorzoli A, Esposito S, Di Carlo E. Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage. Clin Cancer Res. 2014;20(3):585–94. https://doi.org/10.1158/1078-0432.CCR-13-2240.CrossRefPubMed

26.

Hu F, Yuan W, Wang X, Sheng Z, Yuan Y, Qin C, He C, Xu T. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells. Clin Transl Oncol. 2015;17(8):632–9. https://doi.org/10.1007/s12094-015-1288-9.CrossRefPubMed

27.

Xie J, Yuan Y, Liu Z, Xiao Y, Zhang X, Qin C, Sheng Z, Xu T, Wang X. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities. Clin Transl Oncol. 2014;16(4):402–9. https://doi.org/10.1007/s12094-013-1092-3.CrossRefPubMed

28.

Li Z, Xie J, Wu J, Li W, Nie L, Sun X, Tang A, Li X, Liu R, et al. CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PLoS ONE. 2014;9(2):e88965. https://doi.org/10.1371/journal.pone.0088965.CrossRefPubMedPubMedCentral

29.

Zhang H, Zhang J, Nan X, Li X, Qu J, Hong Y, Sun L, Chen Y, Li T. CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma. Tumour Biol. 2015;36(10):7849–58. https://doi.org/10.1007/s13277-015-3504-1.CrossRefPubMed

30.

Lu M, Huang Y, Sun W, Li P, Li L, Li L. miR-135b-5p promotes gastric cancer progression by targeting CMTM3. Int J Oncol. 2018;52(2):589–98. https://doi.org/10.3892/ijo.2017.4222.CrossRefPubMed

31.

Yuan W, Liu B, Wang X, Li T, Xue H, Mo X, Yang S, Ding S, Han W. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer. Cancer Lett. 2017;386:77–86. https://doi.org/10.1016/j.canlet.2016.11.015.CrossRefPubMed

32.

Yuan W, Li T, Mo X, Wang X, Liu B, Wang W, Su Y, Xu L, Han W. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway. Oncotarget. 2016;7(20):29507–19. https://doi.org/10.18632/oncotarget.8789.CrossRefPubMedPubMedCentral

33.

Su Y, Lin Y, Zhang L, Liu B, Yuan W, Mo X, Wang X, Li H, Xing X, et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci. 2014;105(1):26–34. https://doi.org/10.1111/cas.12304.CrossRefPubMed

34.

Dong W, Li J, Dong X, Shi W, Zhang Y, Liu Y. MiR-17 and miR-93 promote tumor progression by targeting p21 in patients with chordoma. Onco Targets Ther. 2021;14:3109–18. https://doi.org/10.2147/OTT.S307138.CrossRefPubMedPubMedCentral

35.

Li L, Lv G, Wang B, Ma H. Long noncoding RNA LINC00525 promotes the aggressive phenotype of chordoma through acting as a microRNA-505-3p sponge and consequently raising HMGB1 expression. Onco Targets Ther. 2020;13:9015–27. https://doi.org/10.2147/OTT.S268678.CrossRefPubMedPubMedCentral

36.

Chen L, Zuo Y, Pan R, et al. GSK-3beta regulates the expression of P21 to promote the progression of chordoma. Cancer Manag Res. 2021;2021(13):201–14. https://doi.org/10.2147/CMAR.S289883.CrossRef

37.

Chen H, Garbutt CC, Spentzos D, Choy E, Hornicek FJ, Duan Z. Expression and therapeutic potential of SOX9 in chordoma. Clin Cancer Res. 2017;23:5176–86. https://doi.org/10.1158/1078-0432.CCR-17-0177.CrossRefPubMedPubMedCentral

38.

Wang J, Hu W, Du X, Sun Y, Han S, Tu G. Fingolimod inhibits proliferation and epithelial-mesenchymal transition in sacral chordoma by inactivating IL-6/STAT3 signalling. Biosci Rep. 2020. https://doi.org/10.1042/BSR20200221.CrossRefPubMedPubMedCentral

39.

Zhao K, Li X, Chen X, et al. Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression. Eur J Pharmacol. 2019;854:298–306. https://doi.org/10.1016/j.ejphar.2019.03.034.CrossRefPubMed

40.

Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017;543:428–32. https://doi.org/10.1038/nature21409.CrossRefPubMedPubMedCentral

41.

Faheem MM, Seligson ND, Ahmad SM, Rasool RU, Gandhi SG, Bhagat M, Goswami A. Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives. Cell Death Discov. 2020;6:51. https://doi.org/10.1038/s41420-020-0286-z.CrossRefPubMedPubMedCentral

42.

Kosvyra A, Maramis C, Chouvarda I. Developing an integrated genomic profile for cancer patients with the use of NGS data. Emerg Sci J. 2019;3(3):157–67. https://doi.org/10.28991/esj-2019-01178.CrossRef

43.

Choi S, Chen M, Cryns VL, Anderson RA. A nuclear phosphoinositide kinase complex regulates p53. Nat Cell Biol. 2019;21(4):462–75. https://doi.org/10.1038/s41556-019-0297-2.CrossRefPubMedPubMedCentral

44.

Abdelaal AM, Attalla EM, Elshemey WM. Estimation of out-of-field dose variation using markus ionization chamber detector. SciMed J. 2020. https://doi.org/10.28991/SciMedJ-2020-0201-2.CrossRef

45.

Agsalda-Garcia M, Shieh T, Souza R, et al. Raman-enhanced spectroscopy (RESpect) probe for childhood non-hodgkin lymphoma. SciMed J. 2020;2:1–7. https://doi.org/10.28991/scimedj-2020-0201-1.CrossRefPubMedPubMedCentral

46.

Tauziede-Espariat A, Bresson D, Polivka M, Bouazza S, Labrousse F, Aronica E, Pretet JL, Projetti F, Herman P, et al. Prognostic and therapeutic markers in chordomas: a study of 287 tumors. J Neuropathol Exp Neurol. 2016;75(2):111–20. https://doi.org/10.1093/jnen/nlv010.CrossRefPubMed

47.

Tosuner Z, Bozkurt SU, Kilic T, Yilmaz B. The role of EGFR, hepatocyte growth factor receptor (c-Met), c-ErbB2 (HER2-neu) and clinicopathological parameters in the pathogenesis and prognosis of chordoma. Turk Patoloji Derg. 2017;33(2):112–20. https://doi.org/10.5146/tjpath.2016.01378.CrossRefPubMed

48.

Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, Turlais F, Ye H, Leite AP, et al. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol. 2016;239(3):320–34. https://doi.org/10.1002/path.4729.CrossRefPubMedPubMedCentral

49.

Asquith C, Maffuid KA, Laitinen T, Torrice CD, Tizzard GJ, Crona DJ, Zuercher WJ. Targeting an EGFR water network with 4-anilinoquin(az)oline inhibitors for chordoma. ChemMedChem. 2019;14(19):1693–700. https://doi.org/10.1002/cmdc.201900428.CrossRefPubMed

50.

Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, et al. Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and Brachyury. Mol Cancer Ther. 2018;17(3):603–13. https://doi.org/10.1158/1535-7163.MCT-17-0324.CrossRefPubMed

51.

Eskilsson E, Rosland GV, Solecki G, Wang Q, Harter PN, Graziani G, Verhaak R, Winkler F, Bjerkvig R, et al. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 2018;20(6):743–52. https://doi.org/10.1093/neuonc/nox191.CrossRefPubMed

52.

Trapani D, Conforti F, De Pas T. EGFR inhibition in a pretreated sacral chordoma: a role for erlotinib? Case report and a brief review of literature. Transl Med UniSa. 2017;16:30–3.PubMedPubMedCentral

53.

Rupp M, Hagenbuchner J, Rass B, Fiegl H, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ. FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3. Oncogene. 2017;36(44):6190–203. https://doi.org/10.1038/onc.2017.288.CrossRefPubMedPubMedCentral

54.

Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu TK, et al. Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas. Cell Rep. 2019;28(5):1370–84. https://doi.org/10.1016/j.celrep.2019.07.001.CrossRefPubMedPubMedCentral

Title: CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway
Authors: Wanqiong Yuan
Feng Wei
Hanqiang Ouyang
Xiaoqing Ren
Jing Hang
Xiaoning Mo
Zhongjun Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02159-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy

Ring finger protein 152-dependent degradation of TSPAN12 suppresses hepatocellular carcinoma progression

Imperatorin induces autophagy and G0/G1 phase arrest via PTEN-PI3K-AKT-mTOR/p21 signaling pathway in human osteosarcoma cells in vitro and in vivo

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma

Silencing SHMT2 inhibits the progression of tongue squamous cell carcinoma through cell cycle regulation

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer